![Pratik Multani](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 3 M $ in data 31/05/2026
Pratik S.
Multani is currently an Independent Director at Erasca, Inc. since 2018, Principal at the American Board of Internal Medicine, and Chief Medical Officer at Oric Pharmaceuticals, Inc. since 2018.
Former positions include Independent Director at Chimerix, Inc. from 2020 to 2025; Chief Medical Officer at Ignyta, Inc. from 2015 to 2017; Chief Medical Officer at Fate Therapeutics, Inc. from 2013 to 2015; Member at Harvard Medical School; Member at The General Hospital Corp.; Principal at Harvard University; Chief Medical Officer at Kanisa Pharmaceuticals, Inc. from 2005 to 2009; Vice President-Clinical Development at Kalypsys, Inc. from 2007 to 2009; Vice President-Clinical Development at Salmedix, Inc. from 2004 to 2005; Senior Director-Medical Research & Development at Biogen, Inc. from 1999 to 2004; and Senior Director-Medical Research at IDEC Pharmaceuticals Corp.
Education includes undergraduate degree from Yale University, doctorate from Harvard Medical School, and graduate degree from Harvard T.H.
Chan School of Public Health.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
ERASCA, INC. 0,06% | 15/04/2026 | 172.866 ( 0,06% ) | 2 M $ | 31/05/2026 |
| 31/03/2026 | 68.149 ( 0,07% ) | 575 859 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ERASCA, INC. | Direttore/Membro del Consiglio | 02/07/2018 |
| ORIC PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2018 |
American Board of Internal Medicine
 American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services Operates self-appointed physician evaluation organization | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
| CHIMERIX, INC. | Direttore/Membro del Consiglio | 21/04/2025 |
| IGNYTA INC | Direttore Tecnico/Scientifico/R&S | 01/01/2017 |
| FATE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2015 |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases | Direttore Tecnico/Scientifico/R&S | 01/03/2009 |
Kanisa Pharmaceuticals, Inc.
 Kanisa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals and provides medical services | Direttore Tecnico/Scientifico/R&S | 01/01/2009 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 16 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases | Health Technology |
Chimerix, Inc.
 Chimerix, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for rare epilepsies, cancers and sleep disorders | Health Technology |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology and small molecule drugs to treat hematologic malignancies | Health Technology |
Kanisa Pharmaceuticals, Inc.
Kanisa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals and provides medical services | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services Functions as a non profit organization that operates general hospital | Health Services |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes targeted immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American Board of Internal Medicine
American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services Operates self-appointed physician evaluation organization | Commercial Services |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Oric Pharmaceuticals, Inc.
 Oric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceutical products | Health Technology |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
